文献速递眼底病与葡萄膜炎

白介素6抑制剂Vamikibart治疗葡萄膜炎性黄斑水肿:1期DOVETAIL非随机临床试验

Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2026-01-01

DOVETAIL是一项多中心、开放标签、多次递增剂量的1期非随机临床试验,评估玻璃体内注射Vamikibart(RO7200220,新型抗白介素6单克隆抗体)单药治疗非感染性葡萄膜炎继发黄斑水肿的安全性与耐受性。37例受试者分3个剂量组(0.25、1、2.5 mg),第1、4、8周给药。结果显示所有剂量组最佳矫正视力与中心亚视野厚度均有改善,未报告视网膜血管炎。

要点

  • 玻璃体内Vamikibart在0.25、1、2.5 mg剂量下均与BCVA和CST改善相关。
  • 第12周平均BCVA字母评分较基线提高+9.9(SD 8.9),约2行改善。
  • 第12周平均CST较基线降低-165.1(SD 147.5)µm。

核心结论

  • 1期DOVETAIL非随机临床试验初步证据支持Vamikibart治疗非感染性葡萄膜炎继发黄斑水肿的安全性、耐受性和潜在疗效。

研究设计与样本

  • 多中心、开放标签、多次递增剂量、非随机1期临床试验,2019年7月至2023年11月在美国18个中心开展。
  • 纳入37例非感染性葡萄膜炎继发黄斑水肿成人患者,OCT中心亚视野厚度≥325 µm。
  • 受试者分3个剂量组(0.25 mg n=12;1 mg n=12;2.5 mg n=13),第1、4、8周玻璃体内注射Vamikibart,随后观察至第20周(2.5 mg组)或第36周(0.25或1 mg组)。
  • 22/37例(59.5%)为女性,平均(SD)年龄63.5(15.4)岁。

主要发现

  • 第12周平均(SD)BCVA字母评分较基线变化为+9.9(8.9),0.25 mg、1 mg、2.5 mg组分别为+11.1(8.1)、+10.3(8.0)、+8.4(10.8)。
  • 第12周平均(SD)CST较基线降低-165.1(147.5)µm,3个剂量组分别为-125.0(135.0)µm、-188.1(152.4)µm、-183.6(159.4)µm。
  • 37例中36例在12周内继续接受Vamikibart治疗。
  • 研究眼 ocular 不良事件报告于19例(51.4%),包括1例严重不良事件(葡萄膜炎加重,与研究药物无关)和1例治疗相关不良事件(暂时性视力下降)。
  • 未报告视网膜血管炎(闭塞性或非闭塞性)病例。

临床怎么用

  • Vamikibart作为一种非甾体类玻璃体内抗IL-6单克隆抗体,可能为非感染性葡萄膜炎继发黄斑水肿提供新的治疗选择。
  • 目前处于1期初步证据阶段,尚需3期临床试验(MEERKAT NCT05642312和SANDCAT NCT05642325)进一步验证。

局限性

  • 非随机、开放标签设计,样本量小(37例),缺乏对照组。
  • 为1期探索性研究,疗效结果需后续随机对照试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Effective nonsteroidal therapies are needed for uveitic macular edema (UME). OBJECTIVE: To assess the safety, tolerability, and effects associated with intravitreal (IVT) vamikibart in UME. DESIGN, SETTING, AND PARTICIPANTS: This multipart, multicenter, open-label, multiple-ascending-dose nonrandomized clinical trial of vamikibart (RO7200220), a novel IVT anti-interleukin 6 monoclonal antibody, included monotherapy in participants with UME secondary to noninfectious uveitis (NIU). DOVETAIL was conducted from July 2019 to November 2023 at 18 sites in the US. Adults with UME secondary to NIU (optical coherence tomography central subfield thickness [CST] ≥325 µm) were eligible for inclusion. Data were analyzed from February 2024 to May 2024. INTERVENTIONS: Participants were enrolled into 3 dose groups (0.25, 1, or 2.5 mg) and received IVT vamikibart at day 1, week 4, and week 8, followed by observation not receiving treatment until weeks 20 (2.5 mg) or 36 (0.25 or 1 mg). MAIN OUTCOMES AND MEASURES: The primary outcomes were safety and tolerability; exploratory outcomes included best-corrected visual acuity (BCVA) and CST. RESULTS: In this nonrandomized study, vamikibart was associated with improvements in BCVA and CST across all doses. A total of 37 participants with UME were enrolled (0.25 mg: n = 12; 1 mg: n = 12; 2.5 mg: n = 13); 22 of 37 patients (59.5%) were female, and the mean (SD) age was 63.5 (15.4) years. At week 12, mean (SD) change from baseline in BCVA letter score was +9.9 (8.9), an approximate 2-line improvement (improvements in letter scores of +11.1 [8.1], +10.3 [8.0], and +8.4 [10.8] for the 0.25-mg, 1-mg, and 2.5-mg groups, respectively), and mean (SD) CST reduction was -165.1 (147.5) µm (-125.0 [135.0] µm, -188.1 [152.4] µm, and -183.6 [159.4] µm for the 3 dose groups, respectively). Of 37 participants, 36 continued vamikibart throughout the 12 weeks. Ocular adverse events (AEs) in the study eye were reported in 19 participants (51.4%), including 1 serious AE (uveitis worsening, unrelated to study drug) and 1 treatment-related AE (VA reduced transiently). No cases of retinal vasculitis (occlusive or nonocclusive) were reported. CONCLUSIONS AND RELEVANCE: These results from the phase 1 DOVETAIL nonrandomized clinical trial provide preliminary evidence supporting safety, tolerability, and potential effects of vamikibart for UME secondary to NIU. Two phase 3 clinical trials (MEERKAT [NCT05642312] and SANDCAT [NCT05642325]) are underway to further evaluate vamikibart in UME. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06771271.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sharma S, Lin P, Hu A, et al. Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized Clinical Trial. JAMA Ophthalmol. 2026. PMID: 41954903. doi:10.1001/jamaophthalmol.2026.0610

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。